The power of the CRISPR/Cas9 technology can be harnessed to both model different types of mutations and correct pathogenic mutations (42, 43), thereby leading, in the case of DMD, to the potential restoration of a full-length dystrophin protein. This evidence concerns the gene DMD and Duchenne muscular dystrophy.